What is Lifesci Capital's Estimate for AVDL Q1 Earnings?

Avadel Pharmaceuticals plc (NASDAQ:AVDL - Free Report) - Equities research analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Avadel Pharmaceuticals in a report released on Monday, March 3rd. Lifesci Capital analyst M. Belghiti expects that the company will post earnings of ($0.04) per share for the quarter. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals' Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.15 EPS.

Other equities analysts also recently issued reports about the stock. UBS Group reduced their target price on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a "buy" rating for the company in a report on Monday, January 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Avadel Pharmaceuticals in a report on Tuesday, February 11th. They issued a "buy" rating and a $12.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $21.00 price objective on shares of Avadel Pharmaceuticals in a research report on Tuesday, March 4th. Needham & Company LLC restated a "buy" rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research report on Monday, March 3rd. Finally, Piper Sandler decreased their target price on Avadel Pharmaceuticals from $24.00 to $13.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Avadel Pharmaceuticals has an average rating of "Buy" and a consensus price target of $19.88.

Remove Ads

Avadel Pharmaceuticals Stock Up 0.4 %

NASDAQ:AVDL traded up $0.03 during mid-day trading on Wednesday, reaching $7.91. The company's stock had a trading volume of 731,675 shares, compared to its average volume of 1,185,152. Avadel Pharmaceuticals has a 1 year low of $7.39 and a 1 year high of $19.09. The stock has a fifty day moving average of $8.57 and a 200-day moving average of $11.37. The firm has a market capitalization of $762.22 million, a PE ratio of -10.01 and a beta of 1.57.

Insiders Place Their Bets

In other news, Director Peter J. Thornton bought 10,000 shares of the firm's stock in a transaction on Monday, January 13th. The shares were bought at an average cost of $8.04 per share, for a total transaction of $80,400.00. Following the completion of the transaction, the director now owns 104,055 shares in the company, valued at $836,602.20. This trade represents a 10.63 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Linda Palczuk bought 5,000 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The stock was acquired at an average price of $7.93 per share, with a total value of $39,650.00. Following the completion of the purchase, the director now directly owns 67,900 shares of the company's stock, valued at approximately $538,447. The trade was a 7.95 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 42,981 shares of company stock valued at $400,005 over the last quarter. Company insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Avadel Pharmaceuticals

A number of large investors have recently modified their holdings of AVDL. Creative Planning boosted its position in Avadel Pharmaceuticals by 8.2% during the 3rd quarter. Creative Planning now owns 12,381 shares of the company's stock valued at $162,000 after purchasing an additional 938 shares during the period. Crossmark Global Holdings Inc. bought a new stake in Avadel Pharmaceuticals during the 3rd quarter valued at $350,000. Aigen Investment Management LP bought a new stake in Avadel Pharmaceuticals during the 3rd quarter valued at $160,000. Oppenheimer & Co. Inc. raised its stake in Avadel Pharmaceuticals by 9.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 33,105 shares of the company's stock valued at $434,000 after acquiring an additional 2,780 shares in the last quarter. Finally, MAI Capital Management raised its stake in Avadel Pharmaceuticals by 1.0% during the 3rd quarter. MAI Capital Management now owns 107,533 shares of the company's stock valued at $1,410,000 after acquiring an additional 1,031 shares in the last quarter. Institutional investors and hedge funds own 69.19% of the company's stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.